| Prev Close | 0.00 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 0.00 / 0.00 |
| Exchange | NYSE |
| Div & Yield | N.A. (N.A) |
Medicis Pharmaceuticals Corporation was a leading decliner within the drugs industry, falling $1.32 (-3%) to $42.03 on heavy volume.
The ex-dividend date for Medicis Pharmaceuticals Corporation (NYSE:MRX) is tomorrow, September 27, 2012. Owners of shares as of market close today will be eligible for a dividend of 10 cents per share. At a price of $43.34 as of 9:30 a.m., the dividend yield is 0.9%.
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Medicis Pharmaceutical Corporation (“Medicis” or the “Company”) (NYSE-MRX) ...
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Medicis Pharmaceutical Corp.
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Medicis Pharmaceutical Corporation (“Medicis” or the “Company”) (NYSE:MRX) ...
Levi & Korsinsky is investigating the Board of Directors of Medicis Pharmaceutical Corporation (“Medicis” or the “Company”) (NYSE: MRX) for possible breaches of fiduciary duty and other violations...
Ryan & Maniskas, LLP ( www.rmclasslaw.
Securities lawyers at Goldfarb LLP are investigating alleged violations of shareholder protection laws by officers and directors of Medicis Pharmaceutical Corporation (NYSE: MRX) in connection with a buyout for $44...
Cramer doesn't want to flee the market and thinks you shouldn't either.
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Medicis Pharmaceutical Corp.
The Dow and S&P 500 close lower, weighed down by disappointing manufacturing data, while the Nasdaq manages a slight gain as Apple rallies.
Levi & Korsinsky is investigating the Board of Directors of Medicis Pharmaceutical Corporation (“Medicis” or the “Company”) (NYSE: MRX) for possible breaches of fiduciary duty and other violations...
Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of Medicis Pharmaceutical Corporation (“Medicis” or the “Company”) (NYSE: MRX) (ISIN: US5846903095)...
Holzer Holzer & Fistel, LLC is investigating whether the directors of Medicis Pharmaceutical Corporation (“Medicis” or the “Company”) (NYSE: MRX) complied with their fiduciary duties in approving...
Rigrodsky & Long, P.A.
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the sale of Medicis Pharmaceutical Corporation...
Kendall Law Group, led by former federal judge Joe Kendall, is investigating Medicis Pharmaceutical Corp.
Stock futures are meandering coming out of the extended Labor Day holiday weekend.
U.S. stock futures are higher; Mario Draghi indicates ECB could buy shorter-dated bonds; Valeant to buy Medicis.
Medicis Pharmaceutical is being acquired by Valeant Pharmaceuticals for $2.6 billion.
Valeant Pharmaceuticals agrees to buy dermatology products maker Medicis Pharmaceutical Corp. for about $2.6 billion in cash.
Medicis Pharmaceutical's CEO Discusses Q2 2012 Results - Earnings Call Transcript
The ex-dividend date for Medicis Pharmaceuticals Corporation (NYSE:MRX) is tomorrow, June 28, 2012. Owners of shares as of market close today will be eligible for a dividend of 10 cents per share. At a price of $33.29 as of 10 a.m., the dividend yield is 1.2%.
The ex-dividend date for Medicis Pharmaceuticals Corporation (NYSE:MRX) is tomorrow, March 29, 2012. Owners of shares as of market close today will be eligible for a dividend of 10 cents per share. At a price of $38.41 as of 9:30 a.m., the dividend yield is 1%.
These stocks, which go ex-dividend Thursday, receive buy ratings from TheStreet Ratings.
